| Literature DB >> 34415627 |
Ahmed El-Nawawy1, Manal Am Antonios1, Marwa A Meheissen2, Marwan M Fahim1.
Abstract
The burden of pneumonia, especially that caused by respiratory viruses, is markedly high in the pediatric age group. This study aimed to assess viral agents causing severe pneumonia among mechanically ventilated patients. Nonbronchoscopic bronchoalveolar lavage was performed for pediatric patients having severe pneumonia indicated for mechanical ventilation to be tested with a multiplex PCR immediate diagnosis of their etiologic pathogen. Among the 75 patients recruited, viral agents were detected in 73.4% of cases. Rhinovirus and respiratory syncytial virus (RSV) were the most common viruses detected in 32.1% and 29.5%, respectively. The rate of viral infection showed a clear increased incidence in the winter season. The mortality rate among viral-associated severe pneumonia reached 56.36%. Odds of mortality increased threefolds in presence of comorbid conditions and 10-folds with congenital heart disease. The study demonstrated the neglected importance of rhinovirus besides RSV in causing severe critical pneumonia in the pediatric age.Entities:
Keywords: bronchoalveolar lavage; rhinovirus; severe pneumonia
Mesh:
Year: 2021 PMID: 34415627 PMCID: PMC8426888 DOI: 10.1002/jmv.27284
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 20.693
Comparison between the studied subgroups
| Only viral ( | Only bacterial ( | Mixed viral and bacterial ( |
| |
|---|---|---|---|---|
| Sex | ||||
| Male | 14 (70.0%) | 9 (60.0%) | 17 (48.6%) | 0.294 |
| Female | 6 (30.0%) | 6 (40.0%) | 18 (51.4%) | |
| 5.50 (4–10.5) | 9.0 (4–56) | 4.50 (3–9) | 0.259 | |
| Age categories | ||||
| <12 | 15 (75.0%) | 8 (53.3%) | 30 (85.7%) |
MC
|
| 12–<60 | 5 (25.0%) | 3 (20.0%) | 4 (11.4%) |
MC
|
| ≥60 | 0 (0.0%) | 4 (26.7%) | 1 (2.9%) |
MC
|
| Summer | 8 (40.0%) | 10 (66.7%) | 6 (17.1%) | 0.003** |
| Fall | 3 (15.0%) | 2 (13.3%) | 8 (22.9%) |
MC
|
| Winter | 6 (30.0%) | 0 (0.0%) | 21 (60.0%) | <0.001** |
| Spring | 3 (15.0%) | 3 (20.0%) | 0 (0.0%) |
MC
|
| PIM 2. median (IQR) | 26.50 (21.4–49.5) | 27.40 (14.7–44.9) | 36.90 (23.6–60) | 0.217 |
| PELOD‐2 median (IQR) | 4.50 (2.5–5.5) | 4.0 (2–4) | 4.0 (4–6) | 0.111 |
| Vital signs mean ( | ||||
| Weak pulsations | 8 (40.0%) | 5 (33.3%) | 20 (57.1%) | 0.227 |
| Temperature (Celsius) | 37.19 ± 1.17 | 37.11 ± 1.27 | 36.90 ± 1.31 | 0.685 |
| Heart rate (bpm) | 149.4 ± 25.43 | 138.0 ± 24.57 | 153.3 ± 26.55 | 0.167 |
| Systolic BP (mmHg) | 98.05 ± 20.11 | 101.8 ± 22.87 | 97.63 ± 15.82 | 0.754 |
| Diastolic BP (mmHg) | 58.15 ± 15.30 | 59.53 ± 19.88 | 55.49 ± 11.84 | 0.634 |
| MAP (mmHg) | 71.80 ± 15.13 | 72.27 ± 21.14 | 69.46 ± 12.20 | 0.783 |
| Respiratory rate (bpm) | 38.89 ± 7.23 | 34.40 ± 8.28 | 47.97 ± 10.01 | <0.001** |
| GCS. median (IQR) | 13.0 (9.5–14) | 14.0 (8.5–15) | 12.0 (8–15) | 0.817 |
| ABG | ||||
| PO2 median (IQR) | 76.05 (63.5–124.9) | 102.0 (77.5–153.5) | 77.0 (63.1–102) | 0.237 |
| PCO2 median (IQR) | 38.95 (34.5–47.5) | 32.0 (26.5–41.5) | 34.90 (31–44.5) | 0.136 |
| PaO2/FiO2 median (IQR) | 125.90 (105.1–220) | 156.0 (131.8–255.5) | 123.30 (83.5–200) | 0.374 |
| WBCs (×103) | ||||
| Total. median (IQR) | 9.40 (7.7–14.3) | 13.80 (6.7–16.5) | 13.30 (7.9–22.2) | 0.463 |
| Neutroph. median (IQR) | 5.70 (3.7–10) | 9.10 (4.1–12.5) | 7.30 (4.5–15.6) | 0.537 |
| Lymph. median (IQR) | 2.28 (1.6–3.3) | 2.50 (1.7–3.6) | 3.20 (1.7–5) | 0.249 |
| Platelets (×103). median (IQR) | 294.0 (200–399) | 176.0 (66.5–467.5) | 250.0 (117–369.5) | 0.393 |
| CRP. median (IQR) | 9.75 (2.3–39.5) | 39.0 (13.8–113.5) | 6.30 (2.3–32.5) | 0.038* |
| Chest X ray | ||||
| Uni‐lobar infiltrate | 3 (15.0%) | 3 (20.0%) | 8 (22.9%) |
MC
|
| Multilobar infiltrates | 2 (10.0%) | 4 (26.7%) | 7 (20.0%) |
MC
|
| Interstitial infiltrates | 12 (60.0%) | 7 (46.7%) | 19 (54.3%) | 0.736 |
| Normal | 3 (15.0%) | 1 (6.7%) | 1 (2.9%) |
MC
|
| Duration MV (days) median (IQR) | 8.0 (3.50–18.0) | 11.0 (3.0–29.50) | 7.0 (4.0–11.0) | 0.721 |
| LOS (days) median (IQR) | 16.0 (9.0–22.0) | 18.0 (7.0–46.50) | 12.0 (6.50–18.0) | 0.239 |
| Outcome. deceased | 12 (60.0%) | 8 (53.3%) | 19 (54.3%) | 0.899 |
Note: MC, monte carlo test. *Statistically significant p ˂ 0.05.
Abbreviations: ABG, arterial blood gases; BP, blood pressure; CRP, C reactive protein; GCS: Glasgow coma scale; IQR, interquartile range; LOS, length of stay; MAP, mean arterial pressure; MV, mechanical ventilation; PELOD, pediatric logistic organ dysfunction; PIM‐2, pediatric index of mortality 2; WBC, white blood cells.
Figure 1RECORD diagram showing the strategy of recruitment of the studied population
Figure 2Trend of viral‐induced pneumonia over 1 year
Figure 3Incidence of respiratory viruses among the studied population
Comparison between the studied groups as regards antimicrobial therapy change after PCR detection of respiratory viruses
| Only viral ( | Only bacterial ( | Mixed viral and bacterial ( |
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |||||
| Addition of antiviral | 11 | 55.0 | 0 | 0.0 | 14 | 40.0 | 11.853** | 0.003** | 0.001** | 0.283 |
| Addition/change of antibiotic | 3 | 15.0 | 9 | 60.0 | 25 | 71.4 | 16.654** | <0.001** | 0.006** | <0.001** |
| Stoppage of antibiotic | 9 | 45.0 | 0 | 0.0 | 0 | 0.0 | 21.425** |
MC
| 0.004** |
FE
|
| No change of antibiotics | 6 | 30.0 | 6 | 40.0 | 6 | 17.1 | 3.141 | 0.208 | 0.537 |
FE
|
Note: χ2: Chi‐square test; MC: Monte Carlo; FE: Fisher Exact.
p: p value for comparing the 3 studied groups
p 1: value for comparing only viral and only bacterial
p 2: value for comparing only viral and mixed viral and bacterial
*Statistically significant at p ≤ .05.
**Statistically significant at p ≤ .01.
Risk factors related to mortality among the subgroup of viral‐induced severe mechanically ventilated pneumonia (n = 55)
| Discharged ( | Deceased ( |
|
| |
|---|---|---|---|---|
| Gender | ||||
| Male | 12 (50.0%) | 19 (61.3%) | 0.701 | 0.402 |
| Female | 12 (50.0%) | 12 (38.7%) | ||
| Age (months) | ||||
| <12 | 21 (87.5%) | 24 (77.4%) | 1.254 |
MC
|
| 12–<60 | 3 (12.5%) | 6 (19.4%) | ||
| ≥60 | 0 (0.0%) | 1 (3.2%) | ||
| Comorbidities | ||||
| Absent | 16 (66.7%) | 11 (35.5%) | 5.263* | 0.022* |
| Present | 8 (33.3%) | 20 (64.5%) | ||
| Comorbidities | ||||
| Asthma | 1 (4.2%) | 0 (0.0%) | 1.316 |
FE
|
| Chronic lung disease | 0 (0.0%) | 1 (3.2%) | 0.789 |
FE
|
| Immunodeficiency | 1 (4.2%) | 3 (9.7%) | 0.609 |
FE
|
| Congenital heart disease | 1 (4.2%) | 10 (32.3%) | 6.672* |
FE
|
| Other | 6 (25.0%) | 10 (32.3%) | 0.345 | 0.557 |
| Addition of antiviral | ||||
| Yes | 11 (45.8%) | 14 (45.2%) | 0.002 | 0.960 |
| No | 13 (54.2%) | 17 (54.8%) | ||
| Stoppage of antibiotic | ||||
| Yes | 2 (8.3%) | 7 (22.6%) | 2.006 |
FE
|
| No | 22 (91.7%) | 24 (77.4%) | ||
| Bacterial coinfection | ||||
| Yes | 16 (66.7%) | 19 (61.3%) | 0.169 | 0.681 |
| No | 8 (33.3%) | 12 (38.7%) |
Note: χ2, Chi‐square test; MC, Monte Carlo; FE, Fisher Exact.
*Statistically significant at p ≤ 0.05.
**Statistically significant at p ≤ 0.01.